



Defining the Future of MR Imaging at the Point of Care

Corporate Presentation | November 2022

© 2022 Hyperfine, Inc.

Forward Looking Statements

This presentation includes forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. All forward-looking statements, including, without limitation, those relating to our operating trends and future financial performance, the impact of COVID-19 or geo-political conflict such as the war in Ukraine, on our business and prospects for recovery, expense management, expectations for hiring, physician training and adoption, growth in our organization, market opportunity, commercial and international expansion, regulatory approvals, and product development are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the “Risk Factors” section of our 10-Q filed with the Securities and Exchange Commission on November 10, 2022.



**Numerous
Challenges**
for patients &
clinicians with MRI
today

High cost limits accessibility



Complex site requirements and upgrades



Scheduling delays lead to longer length of stay



Consumption of valuable personnel resources



Risk of adverse events – today occurring in **22-46% of cases** during transport



Maintaining connection to life support equipment



Single point in time, unable to monitor change in patient condition



Common & Costly Delays to Transfer Patients in the ICU Create Major Unnecessary Costs for Hospitals

Estimated \$300/hr for delays, >\$22,000/week for hospital (>\$1M/year) for large academic center.

Imaging capabilities of MRI, CT and Ultrasound **should be available 24/7/365** at all facilities.

In reality, patients can **wait more than 24 hrs for MRI availability**, resulting in cost for both the patient and the hospital, taking up an ICU bed.



If only there was a way to improve access to imaging...

Point of Care MRI is Poised to Greatly Expand the Existing Imaging Market

>100,000

Swoop installation opportunities
across hospitals and
outpatient care facilities



>\$23 Billion

Total Addressable Market



Our Focus Today: Point of Care Head Imaging for Intensive Care Patients

>100,000
Swoop installation opportunities
across hospitals and
outpatient care facilities

▼
>\$23 Billion
Total Addressable
Market

~2,700
US hospitals providing
ICU services

>5,200
US ICU units

**\$1.3 to
\$1.8 Billion**
US Market Opportunity
in Focus

Swoop® is the Only Portable MRI on the Market



*Installed base includes commercial system installations and research unit installations

Swoop Transforms Care by Bringing MRI to the Patient



Intensive Care Units



Acute Care Settings



Global Health

- Swoop produces images at the point of care, without requiring patient transport
- Alternative to CT with less radiation exposure and excellent detection capabilities
- Improves critical care neuroimaging workflow
- Enables rapid diagnoses and treatment of patients

Significant Clinical Validation and Publications across Renowned Journals



“

Game changer is a good way to put it [...] being able to do the level of sophisticated imaging in an ICU that MRI can provide.”

Dr. Fady Charbel, MD, FAANS, FACS



“

Hyperfine provides me with an opportunity to acquire the information, to interpret the information, and to make a decision based on the information that's in front of me.”

Dr. Shahid Nimjee, MD, PhD, FAANS, FAHA



“

Portable MRI should be used to image any patients in ICUs in any [clinical] setting.”

Dr. Michael Schulder, MD, FAANS



Science Advances, April 2022:

Portable, Low-Field MRI Enables Highly Accessible and Dynamic Bedside Evaluation of Ischemic Stroke

- Imaged 50 confirmed acute ischemic stroke patients; accurately detected infarcts in 45 (90%); captured lesions as small as 4mm

American Journal of Neuroradiology, April 2022:

Implementation of a Low-Field Portable MRI Scanner in a Resource-Constrained Environment: Our Experience in Malawi

- Acquired >260 brain scans; concluded use may lead to faster diagnosis and expedited treatment, including in comatose patients in the E.D. and bed-bound patients with sudden onset neurologic deficits

Nature Communications, August 2021:

Portable, Bedside, Low-Field Magnetic Resonance Imaging for Evaluation of Intracerebral Hemorrhage

- Imaged >140 patients and correctly identified ICH in over 80% of confirmed cases

Swoop Clinical Use Cases in Focus

Neurocritical Care

- Acute Mental Status Change
- Ataxia
- Cerebral Edema
- Cerebrovascular Disease
- Cranial Neuropathy
- Extra Ventricular Drain Placement
- Follow-up Intracranial Hemorrhage
- Follow-up Ischemic Stroke
- Follow-up Hematoma
- Tumor Pre- and Post-Operative


Stroke

- Ischemic Stroke




Current Neuroimaging Workflow with Conventional MRI

Traditional MRI workflow can lead to **prolonged delays** in patient care and **higher resource consumption**



Improved Neuroimaging Workflow with Swoop

Portable MRI workflow enables **timely care and discharge** by bringing brain imaging to the patient's bedside



Multiple Stakeholder Benefits with Swoop



Patient

- Reduced risk of adverse events during transport
- Reduced exposure to radiation from CT
- Greater comfort and convenience
- Faster diagnosis – Improved quality of care



Physician

- Expedited time to diagnosis and treatment
- Discharge patients sooner



Staff

- Better incorporation into workflow by reducing transportation time and risk
- Ergonomic, intuitive, and user-friendly interface



Hospital

- Reduced adverse event rates
- Improved utilization of resources and personnel
- Increased revenue from incremental high-field MRI scans and reduced length of patient stay

Hyperfine is a Compelling Platform for Stroke Diagnosis

15 million

people worldwide
suffer a stroke
annually



MRI scans are better at
**detecting ischemic
stroke damage**
compared to CT scans



Time is brain:
Fast diagnosis
enables wider
range of treatment
options for better
outcomes



Stroke is the **2nd
leading cause
of death** globally

87% strokes
are ischemic
strokes



MRI use for stroke has been
limited due to **lack of access**
to expensive equipment and
experienced neuroradiologists to
interpret results.



Hyperfine offers a
**portable and affordable
MRI platform** that can
perform diffusion imaging
for stroke diagnosis in
multiple care settings,
images can be shared
securely with
neuroradiologists around
the world




Innovative and Agile R&D Engine to Expand Clinical Applications



Financial Profile

2022 Guidance:

- 35-45 commercial system installations
- \$7.0-\$8.0 million in total revenue



Commercial system installations reflect device sales and subscription services through commercial agreements (commercial sales) or through research transfer agreements (“RTA”) sales. Commercial sales are made to hospitals and other healthcare providers as direct sales of devices and software subscription services or through subscriptions for the use of the device and software. RTA sales represent the sale of Swoop units for research use purposes.

2022 bar chart values reflect fiscal year financial guidance, not reported results

Management Team with Proven Track Record of Success



**Maria
Sainz**

President & Chief
Executive Officer



**Alok
Gupta**

Chief Financial
Officer



**Dr. Khan
Siddiqui**

Chief Strategy Officer &
Chief Medical Officer



**Tom
Teisseyre**

Chief Product
Officer



**Mark
Hughes**

VP, Hardware Engineering
& Operations



**Kyla
Pavlina**

Chief People
Officer



**Neela
Paykel**

General Counsel & Chief
Compliance Officer

Thank You!




HYPERFINE

Appendix


Transforming patient care around the world.

The Swoop Portable MR Imaging System is commercially available in the United States, Australia, Canada, New Zealand, and Pakistan. Additionally, Hyperfine has deployed Swoop research systems in Ethiopia, Germany, Ghana, Malawi, the Netherlands, South Africa, Sweden, Uganda, the United Kingdom, and Zambia.




Brain is the Largest MRI Market with Nearly 25% of MR Procedures

MR Procedure Mix, All Sites, by Percent, 2020



Distribution of MR Sites and Procedures, by Site Type, 2020



*Source: 2020 IMV MR Benchmark Report

©2022 Hyperfine, Inc. | Confidential and Proprietary

Demo @ Your Door Successes



HYPERFINE